SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually. The presentation details a ...

Core Viewpoint - The article emphasizes that a HODL strategy may not yield significant alpha or maintain a high Sharpe ratio over the long term, suggesting that active management is essential for maximizing returns and minimizing opportunity costs [1]. Group 1: Investment Strategy - The company advocates for active management in investment strategies to achieve high positive returns, indicating that simply holding assets is insufficient for generating high alpha [1]. - It is highlighted that seeking high returns does not equate to generating high alpha, which is a critical distinction for investors [1]. Group 2: Analyst Background - The analyst has a strong educational background with a degree in Business Economics from UCLA and a Master of Accounting from UMich Ross School of Business, indicating a solid foundation in financial analysis [1]. - The analyst's experience includes 10 years in investment banking and a current role as a senior analyst at a multi-strategy hedge fund, showcasing expertise in fundamental equity research and global macro strategy [1].

光期研究 见微知著 股 指 期 货 策 略 月 报 2 0 2 5 年 6 月 1 光大证券 2020 年 半 年 度 业 绩 E V E R B R I G H T S E C U R I T I E S 股指期货：指数窄幅震荡，基差深度贴水 股指期货 月度要点 1、盘面继续缩量震荡 5月，A股市场窄幅震荡，Wind全A月度上涨2.39%，中证1000上涨1.28%，中证500上涨0.7%，沪深300上涨1.85%，上证50上涨1.73%。 大盘指数自3月起连续3个月表现由于小盘指数，表明股票市场目前主要计价基本面复苏的进度，而资本市场对估值的拉升较为有限。一 季度，国内经济数据整体较2024年有较大提升，这使得政策层面尤其是财政政策相对克制。从4月起，经济数据较一季度环比小幅回落， 使得股票市场继续上涨的动力有待观察，而政策预期目前仍相对偏弱，因此指数整体窄幅震荡。6月，在前期降准降息已经落地的背景 下，预计股市直接利好因素有限，仍将以震荡为主。2025年内的风格切换观察窗口可能位于今年8月。 2、基差铁水幅度较大，主要是由于分红影响 近期，各股指期货的贴水幅度较大，我们认为，股指期货的贴水幅度主要反映市 ...

Core Insights - Genmab A/S announced promising results from the Phase 1/2 RAINFOL™-01 trial for rinatabart sesutecan (Rina-S), showing a 50.0% confirmed objective response rate (ORR) in advanced endometrial cancer patients [2][3][6] - The study involved 64 heavily pre-treated patients, with a median follow-up of 7.7 months, and demonstrated significant anti-tumor activity [3][4] - Rina-S is an investigational antibody-drug conjugate targeting folate receptor alpha (FRα), with ongoing evaluations in various cancers [10][11] Company Overview - Genmab is focused on developing innovative antibody-based medicines to address unmet needs in cancer treatment, particularly for gynecologic cancers [5][12] - The company has a robust pipeline, including bispecific T-cell engagers and antibody-drug conjugates, aiming to transform cancer treatment by 2030 [12] Clinical Trial Details - The RAINFOL-01 trial is an open-label, multicenter study evaluating Rina-S in solid tumors, with specific cohorts for endometrial cancer [6][7] - The B2 cohort results indicate that Rina-S 100 mg/m led to a 50.0% ORR, while the 120 mg/m cohort showed a 47.1% ORR, with no median duration of response reached [3][4][6] Treatment Context - Advanced endometrial cancer has limited treatment options after progression on standard therapies, highlighting the need for new therapies like Rina-S [8][9] - The incidence and mortality rates of endometrial cancer are increasing, emphasizing the urgency for effective management strategies [8] Safety Profile - Common treatment emergent adverse events included diarrhea, dyspnea, and urinary tract infections, with serious adverse events occurring in 31.8% and 50.0% of patients in the 100 mg/m and 120 mg/m cohorts, respectively [4][5] - No significant ocular toxicities or interstitial lung disease were observed, which are often concerns with antibody-drug conjugates [4]

Group 1 - The individual investor aims to build a long track record of compounded returns with a focus on low-risk investments [1] - The investor has achieved a cumulative return of +20% CAGR over five years, emphasizing the importance of discipline and patience in investing [1] - The investment strategy involves researching companies within a specific circle of competence and maintaining a portfolio of 5-15 ideas at a time to generate significant alpha [1] Group 2 - The investor does not provide financial advice but shares ideas and information to foster discussions [3] - There is a beneficial long position in the shares of AMRK, indicating a personal investment interest [2] - The investor's articles are intended to keep a public track record of successful investment ideas rather than serve as financial advice [1][4]

这年头，基金出圈的最好方式就是业绩亮眼。而这，正是中泰天择稳健6个月持有混合（FOF）近期脱颖 而出的原因。 成立于2023年3月21日成立，截至2025年3月31日，中泰天择稳健6个月持有混合（FOF）A份额的份额净 值增长率为7.40%（同期业绩比较基准收益率4.19%），该份额近1年的收益率同类排名2/179（注）。 在许多FOF投资者更关注怎么选出优秀、黑马基金经理时，唐军却选择把切入点放在了 资产配置 上。 传统的基金研究往往是从寻找优秀的基金管理人出发，比如对基金过去收益、风险、风险调整后收益等各 类指标进行比较，综合评价和筛选出优秀的基金。从实践经验来看，这种评定结果主要选出了历史业绩好 的基金，容易集中在迎合过去市场风格的一类基金里。相反， 唐军选择先形成配置观点，然后从配置工 具的角度出发，在各个风格和各类子策略里优选最佳基金，作为实现配置观点的最优工具。 近期，我们邀请唐军和投资者就配置和组合构建等问题做了一次小范围的交流，以下是小编精选出的7个 问答，和大家分享。 问题 你如何构建多元资产组合？ 唐军 主要是基于宏观分析框架来做风险预算，类似于桥水的风险平价模型。但我并不完全进行风险平 ...

Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of the Alpha DaRT for treating solid tumors [3] - The technology behind Alpha DaRT was developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University [3] Product Information - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) utilizes intratumoral delivery of radium-224 impregnated sources to provide highly potent and conformal alpha-irradiation of solid tumors [4] - The therapy aims to destroy tumors while sparing surrounding healthy tissue, as the alpha-emitting atoms diffuse only a short distance [4] Upcoming Events - The CFO of Alpha Tau, Raphi Levy, will present at the Jefferies Global Healthcare Conference on June 5, 2025, from 1:25 to 1:55 PM ET in New York, NY [2] - Mr. Levy will also be available for one-on-one investor meetings during the conference [2]

Providing alpha-generating investment ideas. I am an independent investor managing my family's portfolio, primarily via a Self Managed Super Fund. You can expect my articles to deliver a clearly structured, evidence-based thesis. But first and foremost, I encourage readers to judge me on my performance.I have a generalist approach as I explore, analyze and invest in any sector so long there is perceived alpha potential vs the S&P500. The typical holding period ranges between a few quarters to multiple years ...

Transaction to raise up to $1.5 billion in total proceeds upon exercise of warrants, which would make Strive Asset Management one of the largest Bitcoin treasury companies.The combined company will continue to have no outstanding debt for borrowed money after this financing.Strive CEO Matt Cole to discuss the company’s proposed alpha-generating Bitcoin strategies during his 11:54 AM PT keynote on May 27, 2025 at the Bitcoin for Corporations Symposium in Las Vegas, Nevada. DALLAS, May 27, 2025 (GLOBE NEWSWIR ...

I've had a 'Neutral/Hold' outlook on Microsoft (NASDAQ: MSFT ). This was prudent for the initial 3 months, but since the Q3 FY25 earnings release in late Apr'25 (the company has a Jun-ending fiscal year), the stock hasProviding alpha-generating investment ideas. I am an independent investor managing my family's portfolio, primarily via a Self Managed Super Fund. You can expect my articles to deliver a clearly structured, evidence-based thesis. But first and foremost, I encourage readers to judge me on my pe ...